CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$278.06
−1.28%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$280.14
From 52W high−6.87%
Volume1.48M
Market cap$13.27B
P/E (TTM)—
P/S (TTM)3.3x
Div yield—
Key dataSep 18, 2026
Open
$280.14
From 52W high
−6.87%
Volume
1.48M
Market cap
$13.27B
ValuationView details →
P/E (Fwd)
22.6x
EV/EBITDA
73.1x
P/E (TTM)
—
RSI (14)
50.8
MomentumView details →
1D Return
−1.28%
YTD Return
+39.08%
SummaryUpdated Jun 1, 2026
Charles River Laboratories International, Inc. (NYSE:CRL) is a leading contract research organization founded in 1947 and headquartered in Wilmington, Massachusetts. The company went public in 2000 and has grown to become one of the world's largest providers of non-clinical drug development services to the pharmaceutical and biotechnology industries. Charles River operates globally across the United States, Europe, Canada, and the Asia Pacific region, serving as a critical partner in the drug discovery and development process by providing essential testing services, research models, and manufacturing solutions that help bring new medicines to market.
Similar companies
Latest newsMore news →
Charles River Laboratories International, Inc. introduced rapid cell banking programs combining rapid cell bank and release packages with Next-Generation Sequencing characterization to accelerate release timelines for biopharmaceutical and advanced therapy developers.3d agoCharles River Laboratories' stock price extended its decline to 4%.6d agoCharles River Laboratories' stock fell rapidly by 1.1%.6d ago